3-(1H-benzo[d]imidazol-2-yl)pyrazin-2-amine | 581081-27-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 3-(1H-benzo[d]imidazol-2-yl)pyrazin-2-amine
• 英文别名: 2-[(3-Amino)-2-pyrazinyl]benzimidazole；3-(1H-benzimidazol-2-yl)pyrazin-2-amine
• CAS: 581081-27-8
• 化学式: C₁₁H₉N₅
• 分子量: 211.226
• InChiKey: AUIMKLZTQOVGDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(1H-benzo[d]imidazol-2-yl)pyrazin-2-amine 在 吡啶 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 benzyl (4-(2-(2-(3-benzamidopyrazin-2-yl)-1H-benzo[d]imidazol-1-yl)acetyl)phenyl)carbamate
  参考文献：
  名称：

  Synthesis and Metabolic Studies of Host-Directed Inhibitors for Antiviral Therapy

  摘要：

  Targeting host cell factors required for virus replication provides an alternative to targeting pathogen components and represents a promising approach to develop broad-spectrum antiviral therapeutics. High-throughput screening (HTS) identified two classes of inhibitors (2 and 3) with broad-spectrum antiviral activity against ortho- and paramyxoviruses including influenza A virus (IAV), measles virus (MeV), respiratory syncytial virus (RSV), and human parainfluenza virus type 3 (HPIV3). Hit-to-lead optimization delivered inhibitor 28a, with EC50 values of 0.88 and 0.81 mu M against IAV strain WSN and MeV strain Edmonston, respectively. It was also found that compound 28a delivers good stability in human liver S9 fractions with a half-life of 165 min. These data establish 28a as a promising lead for antiviral therapy through a host-directed mechanism.

  DOI：

  10.1021/ml400166b
• 作为产物：
  描述：

  N-(2-Aminophenyl)-3-aminopyrazine-2-carboxamide 、 水 、 在 水 、 乙酸乙酯 、 magnesium sulfate 作用下， 以 溶剂黄146 为溶剂， 反应 4.0h， 以to afford the product (I-80) (0.12 g, 87%) as a yellow solid的产率得到3-(1H-benzo[d]imidazol-2-yl)pyrazin-2-amine
  参考文献：
  名称：

  HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3

  摘要：

  本发明涉及一种公式I的化合物，其可用作GSK-3和Lck蛋白激酶的抑制剂。本发明还提供了包含该发明化合物的药学上可接受的组合物，并提供了使用这些组合物治疗和预防各种疾病的方法，例如糖尿病、阿尔茨海默病和移植排斥反应。

  公开号：

  US20070270420A1

文献信息

• Heteroaryl compounds useful as inhibitors of GSK-3
  申请人：——

  公开号：US20040034037A1

  公开（公告）日：2004-02-19

  The present invention relates to compounds of formula I useful as inhibitors of GSK-3 and Lck protein kinases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes, Alzheimer's disease, and transplant rejection.

  本发明涉及式I的化合物，其可用作GSK-3和Lck蛋白激酶的抑制剂。本发明还提供了包含本发明化合物的药学上可接受的组合物，并提供了利用这些组合物在治疗和预防各种疾病，如糖尿病、阿尔茨海默病和移植排斥等方面的方法。
• Chemical compounds
  申请人：Alberti John Michael

  公开号：US20060084651A1

  公开（公告）日：2006-04-20

  The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medcicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.

  本发明涉及氨基嘧啶衍生物、含有该衍生物的组合物和药物以及制备和使用这些化合物、组合物和药物的方法。这种氨基嘧啶衍生物对于治疗与不当酪氨酸和/或丝氨酸/苏氨酸激酶活性有关的疾病是有用的。
• AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS
  申请人：ALBERTI John Michael

  公开号：US20090318472A1

  公开（公告）日：2009-12-24

  The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.

  本发明涉及氨基吡嗪衍生物、含有这些衍生物的组合物和药物，以及制备和使用这些化合物、组合物和药物的方法。这样的氨基吡嗪衍生物可用于治疗与不适当的酪氨酸和/或丝氨酸/苏氨酸激酶活性相关的疾病。
• Aminopyrazine derivatives and compositions
  申请人：SmithKline Beecham Corporation

  公开号：US07459454B2

  公开（公告）日：2008-12-02

  The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medcicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.

  本发明涉及氨基吡嗪衍生物，含有这些衍生物的组合物和药物，以及制备和使用这些化合物，组合物和药物的过程。这种氨基吡嗪衍生物在治疗与不适当的酪氨酸和/或丝氨酸/苏氨酸激酶活性有关的疾病中是有用的。
• CHEMICAL COMPOUNDS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1606266A2

  公开（公告）日：2005-12-21